SAB Biotherapeutics (SABS) Change in Cash (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Change in Cash data on file, last reported at $10.0 million in Q1 2026.

• Quarterly Change in Cash rose 407.5% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.9 million (up 277.27% YoY) and the FY2025 annual result came in at $1.6 million, up 103.37% from the prior year.
• Change in Cash climbed to $10.0 million in Q1 2026, from -$18.9 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $54.1 million in Q4 2023 to a low of -$42.5 million in Q1 2024.
• A 5-year average of -$1.1 million and a median of -$3.3 million in 2025 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2023 — Change in Cash jumped 706.3% — and 2025, when it plunged 6825.84%.
• Tracing SABS's Change in Cash over 5 years: stood at $6.7 million in 2022, then soared by 706.3% to $54.1 million in 2023, then slumped by 100.5% to -$273209.0 in 2024, then sank by 6825.84% to -$18.9 million in 2025, then soared by 152.94% to $10.0 million in 2026.
• The last three Change in Cash figures came in at $10.0 million (Q1 2026), -$18.9 million (Q4 2025), and $25.7 million (Q3 2025), per Business Quant data.